A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

ribs_resized

EU leaders seek new tools against drug-resistant TB

 

Leaders from the governments of France and the Netherlands today urged funding for new treatment and prevention tools against drug-resistant tuberculosis at a high-level meeting in Brussels, citing the scope of the problem in Europe.

“Because of drug resistance, TB is evolving to become an untreatable disease for a growing number of people,” said Michèle Boccoz, Special Ambassador for fighting against HIV/AIDS and communicable diseases at the French Ministry of Foreign Affairs and International Development. “Investment in research and development now will allow us to have the drugs and vaccines at hand to eventually end the threat of TB as a health problem in Europe.”

“Without tools such as new drugs and vaccines, we know we cannot reach our goals for controlling TB,” said Marja Esveld, senior policy advisor, global health from the Dutch Ministry of Health. “Now is the time to step up the resources to ensure we have the means to effectively end the epidemic and address the emerging threat of drug-resistant TB.”

Read the article here.

 

Recent News and Announcements

May 26th Webinar on MDR-TB treatment with BDQ in children and adolescents: experience from Belarus

DR-TB STAT and the Sentinel Project will host a webinar, MDR-TB Treatment with Bedaquiline in Children and Adolescents: Global Recommendations and Program Experience in Belarus on 26 May 2017 from 10-11am EDT. Co-sponsored by DR-TB STAT and the Sentinel Project, this webinar will begin with an update on global guidelines for the use of new […]

WEBINAR SERIES: MAY 4TH, TB-PRACTECAL TRIAL

Mark your calendar for Thursday, May 4th from 08:30 to 09:30 EST (14:30-15:30 CEST, SAST) for a presentation by Dr. Bern-Thomas Nyang’wa, MD, on the TB-PRACTECAL trial.  The Pragmatic Clinical Trial for More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL) is a multi-center, open label, multi-arm, randomized, controlled phase II-III trial. TB-PRACTECAL, a Médecins Sans Frontières (MSF) sponsored clinical trial, […]

TB Alliance Sublicenses Promising TB Drug from the Medicines Patent Pool

On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP’s license for the treatment […]

Drug to Treat MDR-TB to be Made Available Across India

New Delhi, Apr 11: The Centre has decided to expand the availability of Bedaquiline, a drug used for treatment of drug-resistant tuberculosis, across the country. Union Health Minister J P Nadda said that under the revised National TB Control Programme (RNTCP) in India, the drug is currently available in five cities – Ahmedabad, Delhi, Chennai, Mumbai […]

Webinar Series: April 20th TB-CHAMP Trial

On Thursday, April 20th from 08:30 to 09:30 EST (14:30-15:30 CEST, SAST) Dr. Anneke Hesseling, MBChB, MSc, PhD, gave a presentation on the TB-CHAMP Trial.  The TB-CHAMP Trial is a phase III cluster randomized, double blind, placebo-controlled, superiority multicenter trial that aims to evaluate the efficacy of levofloxacin versus placebo as preventative therapy against MDR-TB in child and […]

Event Calendar

Social Media